Background {#sec1-2054270415593449}
==========

Research is reckoned as an important contributor to the technological and economic development of a country, which is why public and private entities invest large sums of money in it.^[@bibr1-2054270415593449]^ This has recently produced a large amount of literature based on bibliometric analyses of scientific production^[@bibr2-2054270415593449]^ but very few analyses on intellectual property;^[@bibr3-2054270415593449],[@bibr4-2054270415593449]^ thus, it is difficult to quantify the value of indicators such as patents. These analyses are useful in the fields of innovation, technology transfer and industrial competitiveness, as well as to promote investment in innovation and to provide a framework for the trading of the assets of industrial property via patents and trademarks.^[@bibr5-2054270415593449]^

The economic problems in recent years have affected all countries, with short- and medium-term consequences, particularly related to lack of confidence. Confidence in the future depends greatly on the capacity for innovation shown by businesses and the state.

Investment in knowledge creation had increased in recent years, reaching about 1.1 billion dollars in 2009.^[@bibr5-2054270415593449]^ The demand for industrial property fell in 2009, but despite the difficult economic conditions, it recovered in 2010. The recovery in international patent filings observed in 2010 gained strength in 2011.^[@bibr6-2054270415593449]^

Among the countries with the highest number of patent applications through the Patent Cooperation Treaty in 2011 are Saudi Arabia (81.48%), China (33.42), Ukraine (26.60), Russia (20.80), Japan (20.95), Poland (19.59), Mexico (18.84), Austria (17.79), Brazil (17.21), Belgium (12.78), Turkey (12.70), Denmark (11.83) and India (11.19). However, countries such as Malaysia (−24.28), Hungary (−17.44), Portugal (−17.24), Netherlands (−14.00), Ireland (−4.96), Finland (−2.71), Spain (−2.65), Luxembourg (−1.99), Australia (−1.80), Israel (−1.62) and the United Kingdom (−0.96) had a smaller growth.

Patents in this context are the result of a big effort in innovation. Thus, the connection between science and politics is a priority for the European Union, as it was agreed in the Lisbon Strategy for Growth and Jobs.^[@bibr7-2054270415593449]^ It is therefore important to be aware of the evolution of patents in the specific setting of scientific knowledge, in order to analyse the possible opportunities and forms of future development. The 2008 Compendium of Patent Statistics established a series of very interesting conclusions about patents, particularly in such fields as information and communication technology, nanotechnology, biotechnology, technologies related with the environment, nuclear energy and fuel cells.^[@bibr8-2054270415593449]^

Despite that the generation and transfer of knowledge between science and industry are very important to achieve a good technological balance, bibliometric studies on patents are scarce in specific areas of knowledge.^[@bibr9-2054270415593449]^

Methods {#sec2-2054270415593449}
=======

A search about patents applied internationally in the field of immunology was carried by using the SCOPUS™ database. SCOPUS gives information about over 23 million patents.

For this study, only patent applications under the Patent Cooperation Treaty were considered. The patents were obtained by using the search term 'immunology' in the years 2004 to 2011 during February of the following year.

Obtained data from patents were: inventors and applicants, their nationalities, and sections, classes and subclasses of the International Patent Classification (IPC), using eighth version 2008.01 (<http://www.wipo.int/classifications/ipc/en>).

Results {#sec3-2054270415593449}
=======

Evolution by countries {#sec4-2054270415593449}
----------------------

A search in the SCOPUS database for immunology patents produced a total of 17,281 patent applications during 2004--2011 of which 16,811 were from 30 Organisation for Economic Cooperation and Development (OECD) countries and 5326 from 28 countries in the European Union.

The analysis of these patents shows that they were granted in 89 countries; 13,699 (79.27%) of them were submitted by researchers from only one country, 2781 by researchers from two countries, 446 by researchers from three countries, 74 by researchers from four countries, 5 by researchers from five countries, 3 by researchers from six countries, and only one by researchers from eight countries.

It was in the year 2007 that we found the highest number of patent applications, and from that year it decreased progressively in all countries, except China ([Table 1](#table1-2054270415593449){ref-type="table"}). Table 1.Evolution of immunology patents managed under the Patent Cooperation Treaty agreement during 2004--2011.Country200420052006200720082009201020112004--2011United States1,0691,3011,6601,7381,5841,33981995410,464Great Britain186163199259218197132941,448Germany1561771892101881801111001,311Switzerland978010913412313993106881France831041471331341027068841Canada6679103102106744656632Israel59771038779896762623Australia8576898696676240601Holland5765689082522934477Japan6868819758443518469Italy3543746548503435384Belgium2535546169672931371Denmark841564953483126341Sweden2937366162362118300Austria422527352424149200Spain2323273125241525193China1619182716202636178South Korea131935202825156161India72329252024913150Singapore711202619212317144All the countries Patents1,8372,0902,6562,8282,6022,2181,5551,49517,281^[a](#table-fn1-2054270415593449){ref-type="table-fn"}^ From one country1,4971,6842,1402,2932,0401,7621,1141,16913,699 From several countries3293845135205184522993053,320OECD Patents1,8052,0302,5942,7512,5162,1741,5091,43216,811European Union -28 Patents60664080888080127174554185,326[^1]

Despite the recovery in the number of patent applications produced in 2011 in the field of immunology, there was still a reduction in international patent applications. Likewise, the so-called emerging countries have hardly any patents applied through Patent Cooperation Treaty in recent years.

The United States was the main patent applicant with 10,464 (60.55% of the total), 8445 were carried out just by US researchers and 2019 together with researchers from other countries, 60.02% of patents from OECD and 38.85% from the European Union were granted to researchers from one single country ([Table 1](#table1-2054270415593449){ref-type="table"}).

Productive sectors {#sec5-2054270415593449}
------------------

Private entities produced 10,793 (62.45%) of all patents, followed by universities (3022, 17.48%) and hospitals (588, 3.40%); the other 1960 came from Public Research Organizations (PROs) and, mostly, private applicants.

On the few occasions when there has been collaboration between different sectors, in most cases this has been established between private entities and universities; collaborations between universities and hospitals are very few ([Table 2](#table2-2054270415593449){ref-type="table"}). Table 2.Evolution of immunology patents managed under the Patent Cooperation Treaty agreement during 2004--2011, by productive sector.Year20042005200620072008200920102011TotalPrivate entities1,2471,3071,69518031,5481,30496392610,793Universities2153124555084894243402793,022Hospitals539791108113664218588Others2312462903042602851771671,960Private entities + universities2334434050423140303Private entities + hospitals61615612135477Private entities + others191415152739159153Universities + hospitals6986117121069Universities + others1620272035261830192Hospitals + others9895448249Private entities + universities + hospitals200030128Private entities + universities + others4032423523Private entities + hospitals + others100003015Universities + hospitals + others3522230219Private entities + universities + hospitals + others010000001

Productive areas {#sec6-2054270415593449}
----------------

Patents in immunology are assigned mainly (9212) in subclass A61K (preparations or medical dressing, dental), 5455 to C07K (peptides), 3987 to C12N (microorganisms or enzymes, compositions thereof, spread, preservation or maintenance of microorganisms, mutation or genetic engineering), 3865 to A61P (therapeutic activity of chemical compounds or medicinal preparations), and 3097 to G01N (investigating or analysing materials by determining their chemical or physical properties) ([Table 3](#table3-2054270415593449){ref-type="table"}). Table 3.Distribution by international patent classification section, class and subclasses, of the Immunology patents managed under the Patent Cooperation Treaty agreement during 2004--2011.SectionClassSubclassYear% 2011/ maximum20042005200620072008200920102011**Total**Aall1,5151,5962,3172,7192,3002,019100290214,37033.17A01all80737495968681561,49358.33A01K453533453218191023722.22A01N2828152939453334251**75.55**A01H71024202211271113240.74A23all3843253225256720116.27A23L2222121712154510922.72A61all1,3951,4401,6882,5901,9081,85994587512,70033.78A61K9851,1401,1231,7271,2691,2338958409,21248.63A61P3322305207825925814084203,865**53.70**A61B4135111599241269.75A61L61512141719910102**58.82**A61F7671776635917**.**64Ball56563427432447829514**.**28B01all241412131015659920**.**83Call2,1862,1761,7752,4761,8851,72296886314,05134**.**85C07all1,1431,1418401,2989028436475207,33440**.**06C07K8798776148036536555074675,455**53.12**C07D141141123386150127119951,28224**.**61C07H919377776353324052643**.**01C07C20171723250121112544**.**00C08all21418191914413103**68.42**C12all1,0271,0048961,1199398354824626,76441**.**28C12N6326134856445164723362893,98744**.**87C12Q2973053163493312781631622,20146**.**41C12P8068829671615561574**63.54**C12M1396251112999436**.**00C40all105153019221625142**83.33**D + E + F  + Hall88711131630660**.**00Gall4134874405274924142782973,348**56.35**G01all3894563984794433872772883,117**60.12**G01N3884523974744423842742863,097**60.33**G06all23293744472641322327**.**65G06F22263036321431117430**.**55None0365305916857254291725**.**00

Top applicants {#sec7-2054270415593449}
--------------

The University of California (US) with 315 patent applications was the largest filer among educational institutions, followed by Johns Hopkins University (US), the University of Texas (US), the University of Harvard (US) and the University of Michigan (US).

Likewise, the top five applicant companies with highest number of patent applications in the Patent Cooperation Treaty during this period were Genentech Inc. (US), Novartis AG (CH), Abbott Lab (US), Wyeth Corp (US) and Glaxo Group Ltd (GB) ([Table 4](#table4-2054270415593449){ref-type="table"}). Table 4.Entities with the highest production of patents during 2004--2011.EntitiesPatentsUniv California \[US\]315Genentech Inc \[US\]302Novartis AG \[CH\]268Abbott Lab \[US\]155Wyeth Corp \[US\]152Glaxo Group Ltd \[GB\]148US Government \[US\]146Univ Johns Hopkins \[US\]137Hoffmann la Roche (CH)130Amgen Inc \[US\]122Inst Nat Sante Rech Med \[FR\]122Univ Texas \[US\]118Centocor Inc \[US\]112Schering Corp \[US\]108Yeda Res & Dev \[IL\]100Pfizer Prod Inc \[US\]97Harvard College \[US\]91GlaxoSmithKline Biolog SA (BE)83Scripps Research Inst (US)78Dana Farber Cancer Inst Inc (US)77Gen Hospital Corp \[US\]77Merck & Co Inc (US)76Univ Michigan (US)74Biogen Idec Inc \[US\]73Astrazeneca AB \[SE\]72SmithKline Beecham Corp \[US\]71Pasteur Institut (FR)69Centre Nat Rech Scient (FR)68Zymogenetics Inc \[US\]65Univ Leland Stanford Junior \[US\]63Univ Florida (US)53

Patents and population and gross national income {#sec8-2054270415593449}
------------------------------------------------

The applications published by each country showed no correlation with population size or with its gross national income per capita ([Table 5](#table5-2054270415593449){ref-type="table"}). Table 5.Countries by published patents, population and gross national income per capital.CountryPatents 2004--2011Population by millions inhabitantsGross national income per capita/billions of dollarsUS10,46430746,360GB1,4486241,370DE1,3118242,450CH881865,430FR8416342,620CA6323441,980IL623725,790AU6012243,770NL4771748,460JP46912838,080IT3846035,110BE3711145,270DK341659,060SE300948,840AT200846,450ES1934632,120CN1781,3313,650KR1614919,830IN1501,1551,220SG144537,220

Discussion {#sec9-2054270415593449}
==========

This is one of the first systematic reviews of patents to analyse countries, authorship details, centres and research fields. Studies on patents are useful to ensure effective research funding from both public and private organisations. These studies stimulate research and technological innovation, and are quite important for improving indicators that measure the benefit of the innovation.^[@bibr10-2054270415593449]^

The Knowledge Society is changing, not just academically (Bologna Plan, or the lesser known Alexandria Plan) but also in areas like science, technology and economy; progress and wealth sources that affect the quality of life. Technological innovations in immunology are contributing to the design of new drugs and new methods of clinical diagnosis. Future models, dealing with basic homeostasis, immunity against pathogens, antigen presentation mechanisms, cytokines, mechanisms of autoimmunity, gene recombination, cell cycle regulation, signal transduction and cell sociology will all generate patentable advances such as vaccines and/or treatments.

From the research and development (R&D) point of view, immunology covers three main areas. First, immunodiagnostics, which uses the processing and analysis of images to detect abnormalities in the immune system during the early stages of a disorder, thus reducing the healthcare costs for the health care-provider. Second, immunotechnology, which takes elements from the immune system to be used as drugs, thus acting more efficiently and with fewer adverse effects on the relevant cells and areas of the organism. And third, immunotools, which uses elements of the immune system for the detection, localisation, management and repair of damaged organs and tissues.

Development and progress in science, technology and economy in immunology, as in many other fields, are determined by different factors, such as a more business-oriented culture; in order to improve this, some universities have already incorporated into their study plans subjects related to how to start up a business and support programme to strengthen the connection between R&D and businesses. It is also important to note the fact that due to the current economic situation business people are changing their minds in this respect, and they are seen to be more willing to welcome this kind of collaboration.^[@bibr11-2054270415593449]^

History has shown that countries and companies that invested in new products and innovative activities during periods of economic recession have found themselves in an optimal position to take advantage from the situation once the economy has recovered.^[@bibr12-2054270415593449]^

Patent applications, as a whole, decreased in 2009 but began increasing in 2010 and 2011. However, the trend in immunology was decreasing until 2011, which was not expected by the World Intellectual Property Organization (WIPO) for 2020.^[@bibr13-2054270415593449]^

It is important to notice the scarce collaboration between different economic sectors in immunology. As the president of the European Patent Office said, the most successful countries in innovation are the ones that promote a good cooperation between universities, research centres and industries.^[@bibr14-2054270415593449]^

In immunology, this collaboration between public and private research sectors should therefore be supported and encouraged, although this is not a definitive solution.^[@bibr15-2054270415593449]^

At the same time, the inter-institutional collaboration is maintained in a conceptually elusive and difficult area to achieve, for various reasons such as: cultural clashes, overly bureaucratic agencies, rewards poorly designed or ineffective management of the offices of university technology transfer.^[@bibr16-2054270415593449]^

The organisations that fund research want results to be easily measured (articles or impact factors) and the researchers themselves try to fill their curriculum with the sort of contributions that work faster. The goals of research are sometimes confused with the means of making the results known.

To establish a good connection between sectors, it is necessary to establish clear criteria for the selection of partners and addressing conflicts of interest; likewise, cooperation can sometimes interfere with academic freedom and altruistic research.

It is shown that immunology patents are assigned to fewer sections, classes and subclasses of the International Patent Classification during the last two years.

The cultural tradition in the European Union and the cultural and economic ties with the United States make this country the main technological partner for researchers. Almost half of all patents are presented together with a United States partner. China is starting its internationalisation.

Less than 20% of patents come from universities, although some of them are part of the group of entities that have the most patents in immunology.

In 2008--2009, expenditure on R&D&i is maintained despite the financial crisis. In the European Union, the fall of Gross Domestic Product was higher than the amounts allocated to R&D, producing a net effect of increasing the percentage of investment in R&D&i.

It is also important to consider the impact of intellectual property rights protection on the growth rate of a country. Regression techniques have shown that in countries with a Gross Domestic Product below 3400 US dollars (in 1980 dollars) there is no significant relation between intellectual property rights and growth, but above this threshold the relation is significantly positive.^[@bibr17-2054270415593449]^

Falvey et al.^[@bibr17-2054270415593449]^ found that those countries that gave greater intellectual property rights protection were more attractive destinations for foreign patents. Countries need companies to investigate and put products on the market; otherwise, the countries will become technological colonies of other countries.
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[^1]: 262 patents do not specify the nationality or the researchers or the applicants.
